How Smart Questionnaires and the WHO Skin App are Taking AI into Endemic Communities
In the global fight against leprosy, early case detection is the only definitive way to interrupt transmission. Historically, this required in-person clinical exams conducted by rare medical specialists. Publications from June 2024 reveal a technological shift: field-ready AI applications are moving diagnosis away from centralized hospitals and directly into the hands of community health workers.
The WHO Skin NTD App and Field Algorithms
A prime example of this frontline revolution is the WHO Skin NTD mobile application reviewed in mid-2024. This software brings logical offline and AI algorithms directly to smartphones to tackle skin-related Neglected Tropical Diseases (NTDs), with a major emphasis on leprosy.
The app operates seamlessly in areas with minimal internet connectivity, allowing rural healthcare workers to take photos of suspicious skin lesions. The integrated AI algorithm then compares the image metadata against massive datasets of dermatological manifestations. In 2024 field testing across endemic nations like Kenya, these smartphone-based AI algorithms achieved a diagnostic sensitivity of roughly 80% compared to certified dermatologists. By supporting multiple languages—such as English, French, and Kinyarwanda—the app allows minimally trained local workers to accurately triage leprosy cases right at the patient’s doorstep.
MaLeSQs: The Machine Learning Tool for Neurological Screening
Simultaneously, major breakthroughs advanced the validation of the Leprosy Suspicion Questionnaire (LSQ). The LSQ is a digital screening framework consisting of 14 specific questions focused entirely on early neurological indicators, such as a loss of thermal sensitivity or difficulty buttoning a shirt.
In 2024, researchers perfected MaLeSQs (Machine Learning Leprosy Suspicion Questionnaire), an AI framework that evaluates a patient’s combined answers. Utilizing four distinct mathematical learning paradigms (including Support Vector Machines and Random Forest), MaLeSQs utilizes “Shapley values” to weigh the clinical significance of a patient’s responses.
When deployed alongside new multi-antibody blood biomarkers, this AI questionnaire tool achieved a staggering 100% sensitivity during validation studies. It accurately flagged all early-stage, asymptomatic individuals who harboured the Mycobacterium leprae bacillus before they developed visible physical deformities. This affordable, scalable combination paves a clear path toward national, large-scale screening programs designed to systematically wipe out leprosy transmission cycles globally.